Abstract
Clinical responses to the HER1 (EGF receptor) inhibitors and HER2/neu/ErbB2 inhibitors correlate with high levels of receptor expression. However, a significant subset of patients with high receptor levels appear to be refractory to treatment. We have observed similar results in the 60 cell lines of the NCI Anti-Cancer Drug Screen using a panel of 11 selective HER1 inhibitors. As expected, low HER1-expressing cell lines were insensitive to HER1 inhibitors. In cell lines with high HER1 expression, low concentrations of HER1 inhibitors potently inhibit both HER1 phosphorylation and the mitogen-activated protein kinase (MAPK) pathway. However, this inhibition did not always correlate with cellular arrest. High HER1-expressing cell lines can be subdivided into two groups based on their sensitivity to HER1 inhibitors. In the sensitive group, receptor and growth inhibition was concordant and occurred at sub-micromolar concentrations of HER1 inhibitors. In the insensitive group, receptor inhibition occurred at a low concentration (<1 μM) but concentrations that were ten times or higher were required for growth inhibition. Also, neither induction of p21 and cyclin D1 nor p53 status could explain the difference between sensitive and insensitive cells. Although EGF activated the MAPK pathway in all cell lines, only drug-sensitive cell lines responded to EGF (accelerated entry from G1 to S) and to HER1 inhibitors (G1 arrest) by changes in cell cycling. Furthermore, an EGF-dependent immortalized mammary epithelial cell line was extremely sensitive to a panel of HER1 inhibitors. We infer that independence from mitogen-mediated signaling confers insensitivity to HER1 inhibitors in a large subset of cancer cell lines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bishop PC, Bates SE, Liu ET . 1999 Seminars in Breast Disease 2: 200–213
Blagosklonny MV, Bishop PC, Robey R, Fojo T, Bates SE . 2000 Cancer Res. 60: 3425–3428
Blagosklonny MV, Pardee AB . 2001 Cell cycle checkpoints and cancer Blagosklonny MV (ed) Landes Bioscience: Austin, TX pp. 52–64
Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA . 1996 J. Med. Chem. 39: 267–276
Darzynkiewicz Z . 1995 J. Cell. Biochem. 58: 151–159
de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW . 1998 Genes Dev. 12: 2434–2442
Fan Z, Mendelsohn J . 1998 Curr. Opin. Oncol. 10: 67–73
Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM . 1998 Proc. Natl. Acad. Sci. USA 95: 12022–12027
Gabrilove J, Mendelsohn J . 1990 Curr. Opin. Oncol. 2: 163–170
Gibbs JB . 2000 J. Clin. Invest. 105: 9–13
Hanahan D, Weinberg RA . 2000 Cell 100: 57–70
Hynes NE . 1993 Semin. Cancer Biol. 4: 19–26
Klohs WD, Fry DW, Kraker AJ . 1997 Curr. Opin. Oncol. 9: 562–568
Levitzki A, Gazit A . 1995 Science 267: 1782–1788
Lowe SW, Jacks T, Housman DE, Ruley HE . 1994 Proc. Natl. Acad. Sci. USA 91: 2026–2030
Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA . 1997 Anticancer Drug Des. 12: 533–541
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, Boyd M . 1991 J. Natl. Cancer Inst. 83: 757–766
Oren M . 1999 J. Biol. Chem. 274: 36031–36034
Pegram MD, Pauletti G, Slamon DJ . 1998 Breast Cancer Res. Treat. 52: 65–77
Ritland SR, Gendler SJ, Burgart LJ, Fry DW, Nelson JM, Bridges AJ, Andress L, Karnes WE . 2000 Cancer Res. 60: 4678–4681
Ross JS, Fletcher JA . 1998 Stem Cells 16: 413–428
Ross JS, Fletcher JA . 1999 Am. J. Clin. Pathology 112: S53–S67
Sherr CJ . 2000 Cancer Res. 60: 3689–3695
Sherr CJ, Roberts JM . 1999 Genes Dev. 13: 1501–1512
Slamon D, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF . 1989 Science 244: 707–712
Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC . 1990 Cancer Res. 50: 6075–6086
Stinson SF, Alley MC, Fiebig H, Mullendore LM, Kenney S, Keller J, Boyd MR . 1992 Anticancer Res. 12: 1035–1054
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET . 1998 J. Natl. Cancer Inst. 90: 1346–1360
Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, Vanosdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD . 1997 Science 275: 343–349
Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA . 2000 Pharmacology Therapeutics 88: 229–279
Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Meyers TC, Weinstein JN, Bates SE . 1997 J. Natl. Cancer Inst. 89: 1505–1515
Zeng YX, El-Deiry WS . 1996 Oncogene 12: 1557–1565
Acknowledgements
We thank Harry Lackey III for his help performing immunoblot experiments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bishop, P., Myers, T., Robey, R. et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21, 119–127 (2002). https://doi.org/10.1038/sj.onc.1205028
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205028
Keywords
This article is cited by
-
Automated single-molecule imaging in living cells
Nature Communications (2018)
-
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Breast Cancer Research and Treatment (2009)
-
Comparing antibody and small-molecule therapies for cancer
Nature Reviews Cancer (2006)
-
Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells
British Journal of Cancer (2004)
-
Prospective strategies to enforce selectively cell death in cancer cells
Oncogene (2004)